The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)-Reference-Cited by-同舟云学术

The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)

Published:1988-12 Issue:24 Volume:37 Page:4671-4677
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Knox Richard J.,Boland Marion P.,Friedlos Frank,Coles Brian,Southan Christopher,Roberts John J.

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference32 articles.

1. 2,4-dinitro-5-ethy- leneiminobenzamide (CB 1954): a potent and selective inhibitor of growth of the Walker carcinoma 256;Cobb;Biochem Pharmacol,1969

2. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells;Roberts;Biochem Biophys Res Commun,1986

3. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-l-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells;Knox;Biochem Pharmacol,1988

4. Studies on the reversal of the selective antitumour effect of the aziridinyl derivative CB 1954 by 4-amino-5-imidazolecarboxamide;Connors;Int J Cancer,1972

5. Studies on the protection by imidazoles against the cytotoxicity of the antitumour alkylating agents melphalan and CB 1954;Hickman;Biochem Pharmacol,1976

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A nitroreductase-responsive fluorescence turn-on photosensitizer for lysosomes imaging and photodynamic therapy;Talanta;2024-08

2. WITHDRAWN: A nitroreductase-responsive fluorescence turn-on photosensitizer for lysosomes imaging and photodynamic therapy;Talanta;2024-04

3. Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells;Archiv der Pharmazie;2023-11-06

4. Refined control of CRISPR-Cas9 gene editing in Clostridium sporogenes: the creation of recombinant strains for therapeutic applications;Frontiers in Immunology;2023-10-05

5. The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach;Bioscience Reports;2023-04